By Nevro Corp. Nov 18, 2024 Nov 18, 2024Updated Nov 18, 2024 ...

Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. See why I will remain on the sidelines on NVRO stock for now.

Nevro’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 37.18%. Image Source: Zacks Investment Research Let’s delve deeper.

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Nevro's full-year 2024 worldwide revenue was $408.5 million, a decrease of 3.9% as reported and 4.0% on a constant currency basis, compared with $425.2 million for full-year 2023.

Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 ...

Nevro Corp. (NVRO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and ...